alzheon.com
Alzheon Presents Data to Support Selection of Patients with Mild Alzheimer’s Disease for Pivotal Study of ALZ-801 Using Precision Medicine Approach
Alzheon Presents Data to Support Selection of Patients with Mild Alzheimer’s Disease for Pivotal Study of ALZ-801 Using Precision Medicine Approach New Clinical Data and Analyses for ALZ-801 and its Active Molecule Tramiprosate Presented at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases FRAMINGHAM, Mass., March 30, 2017 – Alzheon, Inc. today announced the